Drug-induced parkinsonism in the elderly: Incidence, management and prevention

Drugs and Aging

Volumn 29, Issue 2, 2012, Pages 105-118

  López Sendn, Jos Luis ^a,b   Mena, Mara Angeles ^b,c   De Yobenes, Justo Garca ^a,b  

^a Hospital Ramn y Cajal   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c Hospital Ramn y Cajal   (Spain)

Author keywords

Adverse drug reactions; Elderly; Parkinsons disease.

Indexed keywords

AMANTADINE; AMIODARONE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CINNARIZINE; CLEBOPRIDE; DILTIAZEM; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FLUNARIZINE; FLUOXETINE; HALOPERIDOL; LEVODOPA; LITHIUM; METHYLDOPA; METOCLOPRAMIDE; OLANZAPINE; PAROXETINE; QUETIAPINE; RESERPINE; RISPERIDONE; SERTRALINE; TETRABENAZINE; TRIFLUOPERAZINE; TRIHEXYPHENIDYL; VALPROIC ACID; VERAPAMIL;

AGE; CLINICAL FEATURE; COGNITIVE DEFECT; DRUG INDUCED DISEASE; DRUG INDUCED PARKINSONISM; EXTRAPYRAMIDAL SYMPTOM; GERIATRIC PATIENT; HUMAN; INCIDENCE; NONHUMAN; PARKINSONISM; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEX DIFFERENCE; TREATMENT DURATION;

AGED; ANIMALS; HUMANS; INCIDENCE; PARKINSONIAN DISORDERS; RISK FACTORS;

EID: 84856271525     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11598540-000000000-00000     Document Type: Review

References (110)

1. Steck H. Extrapyramidal and diencephalic syndrome in the course of Largactil and Serpasil treatments [in French]. Ann Med Psychol 1954; 112 (25): 737-44
2. Carlsson A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 1959; 11 (2 Pt 2): 490-3
3. Carlsson A. A paradigm shift in brain research. Science 2001; 294 (5544): 1021-4 (Pubitemid 33048804)
4. Freyhan FA. Psychomotility and parkinsonism in treatment with neuroleptic drugs. AMA Arch Neurol Psychiatry 1957; 78 (5): 465-72
5. Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system [in German]. Klin Wochenschr 1960; 38: 1236-9
6. Nguyen N, Pradel V, Micallef J, et al. Drug-induced parkinson syndromes [in French]. Therapie 2004; 59 (1): 105-12
7. de la Fuente-Fernandez R, Schulzer M, Kuramoto L, et al. Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann Neurol 2011; 69 (5): 803-10
8. Thal DR, Del Tredici K, Braak H. Neurodegeneration in normal brain aging and disease. Sci Aging Knowledge Environ 2004; 2004 (23): 26
9. Wilson JA, MacLennan WJ. Review: drug-induced parkinsonism in elderly patients. Age Ageing 1989; 18 (3): 208-10 (Pubitemid 20312522)
10. Micheli FE, Cersosimo MG. Drug-induced parkinsonism. Handb Clin Neurol 2007; 84: 399-416
11. Thanvi B, Treadwell S. Drug induced parkinsonism: a common cause of parkinsonism in older people. Postgrad Med J 2009; 85 (1004): 322-6
12. Hansen TE, BrownWL,WeigelRM, et al.Underrecognition of tardive dyskinesia and drug-induced parkinsonism by psychiatric residents. Gen Hosp Psychiatry. 1992;14(5):340-4
13. Weiden PJ, Mann JJ, Haas G, et al. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiatry 1987; 144 (9): 1148-53 (Pubitemid 17147517)
14. Esper CD, Factor SA. Failure of recognition of druginduced parkinsonism in the elderly. Mov Disord 2008; 23 (3): 401-4
15. Tinazzi M, Antonini A, Bovi T, et al. Clinical and [123I]FPCIT SPET imaging follow-up in patients with druginduced parkinsonism. J Neurol. 2009; 256 (6): 910-5
16. Mena MA, Garcia de Yebenes MJ, Tabernero C, et al. Effects of calcium antagonists on the dopamine system. Clin Neuropharmacol 1995; 18 (5): 410-26
17. Rollema H, Skolnik M, D'Engelbronner J, et al. MPP(+)- like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies. J Pharmacol Exp Ther 1994; 268 (1): 380-7 (Pubitemid 24039112)
18. Friedman JH, Trieschmann ME, Fernandez HH. Druginduced parkinsonism. In: Factor S, Lang AE, Weiner WJ, editors. Drug induced movement disorders. 2nd ed. New York: Blackwell Futura, 2005: 103-9
19. Llau ME, Nguyen L, Senard JM, et al. Drug-induced parkinsonian syndromes: a 10-year experience at a regional center of pharmaco-vigilance [in French]. Rev Neurol (Paris) 1994; 150 (11): 757-62
20. Wenning GK, Litvan I, Tolosa E. Milestones in atypical and secondary Parkinsonisms. Mov Disord 2011; 26 (6): 1083-95
21. Stephen PJ, Williamson J. Drug-induced parkinsonism in the elderly. Lancet 1984; II (8411): 1082-3 (Pubitemid 15211533)
22. Aronson TA. Persistent drug-induced parkinsonism. Biol Psychiatry 1985; 20 (7): 795-8 (Pubitemid 16048572)
23. Nobrega F, Glattre E, Kurland LT, et al. Comments on the epidemiology of parkinsonism including prevalence and incidence statistics for Rochester, Minnesota, 1935-1966. In: Barbeau A, Brunette JR, editors. Progress in neurogenetics. Amsterdam: Excerpta Medica, 1969: 474-85
24. Kuzuhara S. Drug-induced parkinsonism [in Japanese]. Nihon Rinsho. 1997; 55 (1): 112-7
25. Baldereschi M, Di Carlo A, Rocca WA, et al. Parkinson's disease and parkinsonism in a longitudinal study: twofold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 2000; 55 (9): 1358-63
26. Benito-Leon J, Bermejo-Pareja F, Rodriguez J, et al. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov Disord 2003; 18 (3): 267-74 (Pubitemid 36410822)
27. Barbosa MT, Caramelli P, Maia DP, et al. Parkinsonism and Parkinson's disease in the elderly: a community-based survey in Brazil (the Bambui study). Mov Disord 2006; 21 (6): 800-8 (Pubitemid 44028300)
28. Bondon-Guitton E, Perez-Lloret S, Bagheri H, et al. Druginduced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France. Mov Disord 2011; 26 (12): 2226-31
29. Seijo-Martinez M, Castro del Rio M, Rodriguez Alvarez J, et al. Prevalence of parkinsonism and Parkinson's disease in the Arosa Island (Spain): a community-based door-todoor survey. J Neurol Sci 2011; 304 (1-2): 49-54
30. Noyes K, Liu H, Holloway RG. What is the risk of developing parkinsonism following neuroleptic use? Neurology 2006; 66 (6): 941-3 (Pubitemid 43739780)
31. Errea-Abad JM, Ara-Callizo JR, Aibar-Remon C. Druginduced parkinsonism. Clinical aspects compared with Parkinson disease [in Spanish]. Rev Neurol 1998; 27 (155): 35-9 (Pubitemid 29101791)
32. Friedman JH, Skeete R, Fernandez HH. Unrecognized parkinsonism in acute care medical patients receiving neurological consultations. J Gerontol A Biol Sci Med Sci 2003; 58 (1): 94-5 (Pubitemid 36110063)
33. Knol W, Keijsers CJ, Jansen PA, et al. Systematic evaluation of rating scales for drug-induced parkinsonism and recommendations for future research. J Clin Psychopharmacol 2010; 30 (1): 57-63
34. Rajput AH. Parkinsonism, aging and gait apraxia. In: Stern MD, Koller WC, editors. Parkinsonian syndromes. New York: Marcel B Dekker, 1993: 511-34
35. Caligiuri MR, Jeste DV, Lacro JP. Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging 2000; 17 (5): 363-84
36. Ayd Jr FJ. A survey of drug-induced extrapyramidal reactions. JAMA 1961; 175: 1054-60
37. Srinivasan TN, Thara R, Padmavathi R, et al. Relationship of extrapyramidal symptoms to age at onset and drug treatment in middle-aged and elderly schizophrenic patients. Schizophr Res 2001; 47 (1): 69-75 (Pubitemid 32121772)
38. Rajput AH, Offord KP, Beard CM, et al. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 1984; 16 (3): 278-82 (Pubitemid 14041762)
39. Kennedy PF, Hershon HI, McGuire RJ. Extrapyramidal disorders after prolonged phenothiazine therapy. Br J Psychiatry 1971; 118 (546): 509-18
40. Shiroma PR, Geda YE, Mrazek DA. Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry. Pharmacogenomics 2010; 11 (9): 1305-30
41. Kasten M, Bruggemann N, Konig IR, et al. Risk for antipsychotic- induced extrapyramidal symptoms: influence of family history and genetic susceptibility. Psychopharmacology (Berl) 2011; 214 (3): 729-36
42. Alkelai A, Greenbaum L, Rigbi A, et al. Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. Psychopharmacology (Berl) 2009; 206 (3): 491-9
43. Myrianthopoulos NC, Kurland AA, Kurland LT. Hereditary predisposition in drug-induced parkinsonism. Arch Neurol 1962; 6: 5-9
44. Metzer WS, Newton JE, Steele RW, et al. HLA antigens in drug-induced parkinsonism. Mov Disord 1989; 4 (2): 121-8 (Pubitemid 19128934)
45. Mena MA, de Yebenes JG. Drug-induced parkinsonism. Expert Opin Drug Saf 2006; 5 (6): 759-71 (Pubitemid 44669491)
46. Negrotti A, Calzetti S, Sasso E. Calcium-entry blockersinduced parkinsonism: possible role of inherited susceptibility. Neurotoxicology 1992; 13 (1): 261-4
47. Mattos JP, Rosso AL, Correa RB, et al. Movement disorders in 28 HIV-infected patients. Arq Neuropsiquiatr 2002; 60 (3-A): 525-30
48. Reyes MG, Faraldi F, Senseng CS, et al. Nigral degeneration in acquired immune deficiency syndrome (AIDS). Acta Neuropathol 1991; 82 (1): 39-44
49. Allam MF, Campbell MJ, Hofman A, et al. Smoking and Parkinson's disease: systematic review of prospective studies. Mov Disord 2004; 19 (6): 614-21 (Pubitemid 39173013)
50. Sandyk R. Cigarette smoking: effects on cognitive functions and drug-induced parkinsonism in chronic schizophrenia. Int J Neurosci 1993; 70 (3-4): 193-7
51. Lohr JB, Lohr MA, Wasli E, et al. Self-perception of tardive dyskinesia and neuroleptic-induced parkinsonism: a study of clinical correlates. Psychopharmacol Bull 1987; 23 (1): 211-4 (Pubitemid 17111698)
52. Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 1988; 51 (6): 850-4
53. Sethi KD, Zamrini EY. Asymmetry in clinical features of drug-induced parkinsonism. J Neuropsychiatry Clin Neurosci 1990; 2 (1): 64-6 (Pubitemid 20125846)
54. Marti Masso JF, Poza JJ. Drug-induced or aggravated parkinsonism: clinical signs and the changing pattern of implicated drugs [in Spanish]. Neurologia 1996; 11 (1): 10-5 (Pubitemid 26091943)
55. Akbostanci MC, Atbasoglu EC, Balaban H. Tardive dyskinesia, mild drug-induced dyskinesia, and drug-induced parkinsonism: risk factors and topographic distribution. Acta Neurol Belg 1999; 99 (3): 176-81
56. Factor SA. The clinical spectrum of freezing of gait in atypical parkinsonism. Mov Disord 2008; 23 Suppl. 2: S431-8
57. Lee PH, Yeo SH, Yong SW, et al. Odour identification test and its relation to cardiac 123I-metaiodobenzylguanidine in patients with drug induced parkinsonism. J Neurol Neurosurg Psychiatry 2007; 78 (11): 1250-2
58. Kruger S, Haehner A, Thiem C, et al. Neuroleptic-induced parkinsonism is associated with olfactory dysfunction. J Neurol 2008; 255 (10): 1574-9
59. Kim YD, Kim JS, Chung SW, et al. Cognitive dysfunction in drug induced parkinsonism (DIP). Arch Gerontol Geriatr 2011; 53 (2): E222-6
60. Klawans Jr HL, Bergen D, Bruyn GW. Prolonged druginduced Parkinsonism. Confin Neurol 1973; 35 (6): 368-77
61. Rajput AH, Rozdilsky B, Hornykiewicz O, et al. Reversible drug-induced parkinsonism. Clinicopathologic study of two cases. Arch Neurol 1982; 39 (10): 644-6 (Pubitemid 12009439)
62. Anden NE, Carlsson A, Hillarp NA, et al. Noradrenaline release by nerve stimulation of the spinal cord. Life Sci 1965; 4: 129-32
63. Rosenfeld M, Brenner-Lavie H, Ari SG, et al. Perturbation in mitochondrial network dynamics and in complex I dependent cellular respiration in schizophrenia. Biol Psychiatry 2011; 69 (10): 980-8
64. Inoue F, Janikowski AM. Withdrawal akinesia. J Neurol Neurosurg Psychiatry 1981; 44 (10): 958 (Pubitemid 12228450)
65. Nelli AC, Yarden PE, Guazzelli M, et al. Parkinsonism following neuroleptic withdrawal. Arch Gen Psychiatry 1989; 46 (4): 383-4 (Pubitemid 19111494)
66. Kagi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry 2010; 81 (1): 5-12
67. Lee PH, Kim JS, Shin DH, et al. Cardiac 123I-MIBG scintigraphy in patients with drug induced parkinsonism. J Neurol Neurosurg Psychiatry 2006; 77 (3): 372-4
68. Rosebush PI, Mazurek MF. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology 1999; 52 (4): 782-5 (Pubitemid 29120185)
69. Yang SY, Kao Yang YH, Chong MY, et al. Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study. Clin Pharmacol Ther 2007; 81 (4): 586-94
70. Miller DD, Caroff SN, Davis SM, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 2008; 193 (4): 279-88
71. Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord 2007; 22 (3): 313-8 (Pubitemid 46569682)
72. Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo- controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005; 20 (8): 958-63 (Pubitemid 41419510)
73. Fernandez HH, Friedman JH, Jacques C, et al. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 1999; 14 (3): 484-7 (Pubitemid 30011661)
74. Hirose G. Drug induced parkinsonism: a review. J Neurol 2006; 254 Suppl. 3: 22-4
75. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002; 47 (1): 27-38 (Pubitemid 34302921)
76. Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol 2001; 102 (9): 2036-45
77. Marti-Masso JF, Poza JJ. Cinnarizine-induced parkinsonism: ten years later. Mov Disord 1998; 13 (3): 453-6 (Pubitemid 28221497)
78. Asanuma M, Ogawa N, Haba K, et al. Calcium antagonist flunarizine hydrochloride affects striatal D2 dopamine receptors in the young adult and aged rat brain. Arch Gerontol Geriatr 1991; 13 (3): 271-8
79. Padrell MD, Navarro M, Faura CC, et al. Verapamilinduced parkinsonism. Am J Med 1995; 99 (4): 436
80. Miodownik C, Witztum E, Lerner V. Lithium-induced tremor treated with vitamin B6: a preliminary case series. Int J Psychiatry Med 2002; 32 (1): 103-8 (Pubitemid 34606530)
81. Dallocchio C, Mazzarello P. A case of Parkinsonism due to lithium intoxication: treatment with Pramipexole. J Clin Neurosci 2002; 9 (3): 310-1
82. Werner EG, Olanow CW. Parkinsonism and amiodarone therapy. Ann Neurol 1989; 25 (6): 630-2 (Pubitemid 19153874)
83. Armon C. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 1996; 47 (3): 626-35 (Pubitemid 26307288)
84. Arai M. Parkinsonism associated with a serotonin and noradrenaline reuptake inhibitor, milnacipran. J Neurol Neurosurg Psychiatry 2003; 74 (1): 137-8 (Pubitemid 36069058)
85. Gony M, Lapeyre-Mestre M, Montastruc JL. Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs. Clin Neuropharmacol 2003; 26 (3): 142-5 (Pubitemid 36676292)
86. Gregory RJ, White JF. Can sertraline induce parkinson's disease? Psychosomatics 2001; 42 (2): 163-4 (Pubitemid 32180008)
87. Rozzini L, Ghianda D, Trabucchi M, et al. Severe worsening of parkinsonism in Lewy body dementia due to donepezil. Neurology 2004; 63 (8): 1543-4 (Pubitemid 39426311)
88. García-Ruiz PJ, García de Yébenes J, et al. Parkinsonism associated with calcium channel blockers: a prospective follow-up study. Clin Neuropharmacol 1992; 15 (1): 19-26
89. Remington G, Mamo D, Labelle A, et al. A PET study evaluating dopamine D2 receptor occupancy for longacting injectable risperidone. Am J Psychiatry 2006; 163 (3): 396-401 (Pubitemid 44469380)
90. Uchida H, Mamo DC, Mulsant BH, et al. Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. J Clin Psychiatry 2009; 70 (3): 397-405
91. Cabello CR, Thune JJ, Pakkenberg H, et al. Ageing of substantia nigra in humans: cell loss may be compensated by hypertrophy. Neuropathol Appl Neurobiol 2002; 28 (4): 283-91 (Pubitemid 34989290)
92. Muthane U, Yasha TC, Shankar SK. Low numbers and no loss of melanized nigral neurons with increasing age in normal human brains from India. Ann Neurol 1998; 43 (3): 283-7 (Pubitemid 28113589)
93. Itier JM, Ibanez P, Mena MA, et al. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 2003; 12 (18): 2277-91 (Pubitemid 37160872)
94. Serrano A, Menendez J, Casarejos MJ, et al. Effects of cinnarizine, a calcium antagonist that produces human parkinsonism, in parkin knock out mice. Neuropharmacology 2005; 49 (2): 208-19 (Pubitemid 40933759)
95. Solano RM, Casarejos MJ, Menendez-Cuervo J, et al. Glial dysfunction in parkin null mice: effects of aging. J Neurosci 2008; 28 (3): 598-611 (Pubitemid 351159033)
96. Rodriguez-Navarro JA, Casarejos MJ, Menendez J, et al. Mortality, oxidative stress and tau accumulation during ageing in parkin null mice. J Neurochem 2007; 103 (1): 98-114 (Pubitemid 47404223)
97. Richelson E. Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J Clin Psychiatry 1984; 45 (8): 331-6 (Pubitemid 14066277)
98. Meredith GE, Switzer 3rd RC, Napier TC. Short-term, D2 receptor blockade induces synaptic degeneration, reduces levels of tyrosine hydroxylase and brain-derived neurotrophic factor, and enhances D2-mediated firing in the ventral pallidum. Brain Res 2004; 995 (1): 14-22 (Pubitemid 37486010)
99. Fa M, Mereu G, Ghiglieri V, et al. Electrophysiological and pharmacological characteristics of nigral dopaminergic neurons in the conscious, head-restrained rat. Synapse 2003; 48 (1): 1-9 (Pubitemid 36249885)
100. Iwahashi K, Anemo K, Nakamura K, et al. Analysis of the metabolism of haloperidol and its neurotoxic pyridinium metabolite in patients with drug-induced parkinsonism. Neuropsychobiology 2001; 44 (3): 126-8 (Pubitemid 34701618)
101. Ulrich S, Sandmann U, Genz A. Serum concentrations of haloperidol pyridinium metabolites and the relationship with tardive dyskinesia and parkinsonism: a cross-section study in psychiatric patients. Pharmacopsychiatry 2005; 38 (4): 171-7 (Pubitemid 41059224)
102. Carlsson A, Carlsson ML. Adaptive properties and heterogeneity of dopamine D(2) receptors: pharmacological implications. Brain Res Rev 2008; 58 (2): 374-8
103. Laporte JR, Capella D. Useless drugs are not placebos: lessons from flunarizine and cinnarizine. Lancet 1986; II (8511): 853-4 (Pubitemid 17178047)
104. Saltz BL, Woerner MG, Robinson DG, et al. Side effects of antipsychotic drugs. Avoiding and minimizing their impact in elderly patients. Postgrad Med 2000; 107 (2): 169-78 (Pubitemid 30091708)
105. Fahn WE, Lake CR. Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism. Am J Psychiatry 1976; 133 (8): 940-3
106. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997; 48 (2): 358-62 (Pubitemid 27087603)
107. Hanin B, Lerner Y, Srour N. An unusual effect of ECT on drug-induced parkinsonism and tardive dystonia. Convuls Ther 1995; 11 (4): 271-4 (Pubitemid 26002256)
108. Goswami U, Dutta S, Kuruvilla K, et al. Electroconvulsive therapy in neuroleptic-induced parkinsonism. Biol Psychiatry 1989 Jul; 26 (3): 234-8 (Pubitemid 19173046)
109. Baez MA, Avery J. Improvement in drug-induced parkinsonism with electroconvulsive therapy. Am J Geriatr Pharmacother 2011; 9 (3): 190-3
110. Thanvi BR, Lo TC, Harsh DP. Psychosis in Parkinson's disease. Postgrad Med J 2005; 81 (960): 644-6 (Pubitemid 41498470)